Back to top
more

Royalty Pharma (RPRX)

(Real Time Quote from BATS)

$28.24 USD

28.24
70,603

+0.13 (0.46%)

Updated Apr 26, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 252)

Industry: Financial - Miscellaneous Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RPRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Royalty Pharma PLC falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 495 1,736 2,189 2,062 341
Receivables 37 37 68 39 39
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 742 782 621 596 453
Total Current Assets 1,274 2,555 2,878 2,697 832
Net Property & Equipment 14,089 13,493 13,718 12,368 10,842
Investments & Advances 1,012 736 910 903 678
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 6 29 52
Deposits & Other Assets 7 30 4 23 46
Total Assets 16,382 16,813 17,516 16,020 12,450
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 15 8 6 11 11
Current Portion Long-Term Debt 0 998 0 0 291
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 52 54 58 152 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 95 107 108 145 31
Total Current Liabilities 161 1,167 171 308 333
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 6,135 6,119 7,096 5,817 5,975
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 3 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 6,298 7,288 7,267 6,124 6,308
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 4,011 3,666 3,508 2,866 0
Retained Earnings 2,518 1,965 2,255 1,921 2,825
Other Equity 3,558 3,897 4,488 5,111 3,320
Treasury Stock 3 3 3 2 4
Total Shareholder's Equity 10,084 9,525 10,249 9,896 6,141
Total Liabilities & Shareholder's Equity 16,382 16,813 17,516 16,020 12,450
Total Common Equity 10,084 9,525 10,249 9,896 6,141
Shares Outstanding 597.40 607.20 607.10 607.10 NA
Book Value Per Share 16.88 15.69 16.88 16.30 -0.06

Fiscal Year End for Royalty Pharma PLC falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 495 942 2,178 1,978
Receivables NA 37 38 35 38
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 742 749 740 615
Total Current Assets NA 1,274 1,729 2,954 2,631
Net Property & Equipment NA 14,089 13,230 13,268 13,662
Investments & Advances NA 1,012 876 871 753
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 7 20 29 28
Total Assets NA 16,382 15,856 17,121 17,074
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 15 14 6 7
Current Portion Long-Term Debt NA 0 0 999 998
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 52 13 54 13
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 95 102 113 99
Total Current Liabilities NA 161 128 1,172 1,117
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 6,135 6,131 6,127 6,123
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 11 9 12
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 6,298 6,270 7,308 7,252
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 4,011 4,007 4,031 3,740
Retained Earnings NA 2,518 2,135 2,253 2,217
Other Equity NA 3,558 3,446 3,532 3,868
Treasury Stock NA 3 3 3 3
Total Shareholder's Equity NA 10,084 9,585 9,814 9,822
Total Liabilities & Shareholder's Equity NA 16,382 15,856 17,121 17,074
Total Common Equity 0 10,084 9,585 9,814 9,822
Shares Outstanding 597.40 597.40 598.30 603.20 607.20
Book Value Per Share 0.00 16.88 16.02 16.27 16.18